Going with the Phlow
Pharmaceutical Commerce
Going with the Phlow
“Established just over two years ago, Phlow quickly generated headlines, some of them controversial, as the corporation secured a contract of up to $812 million from the Trump administration to produce essential medicines that were in short supply or had vulnerable supply chains during the COVID-19 pandemic. In November 2020, however, Outsourced Pharma editor Louis Garguilo wrote of Phlow that no biopharma startup ‘has been as misconstrued, hastily judged in strategy and capability, or even labeled ‘political.'”